Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ALPHA 0602

Next Previous
Drug Profile

ALPHA 0602

Alternative Names: Alpha 602; ALPHA-0602; ND-602; Progranulin gene therapy - Alpha cognition

Latest Information Update: 28 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neurodyn
  • Developer AlphaCognition
  • Class Antidementias; Antiparkinsonians; Gene therapies
  • Mechanism of Action Gene transference; Progranulin protein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Spinal muscular atrophy
  • No development reported Amyotrophic lateral sclerosis
  • Discontinued Alzheimer's disease; Parkinson's disease

Most Recent Events

  • 28 May 2024 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in Canada (Parenteral)
  • 15 Feb 2024 ALPHA 0602 is available for licensing as of 12 Feb 2024. https://www.alphacognition.com/contact/
  • 27 Sep 2023 Preclinical trials in Spinal muscular atrophy in Canada (Parenteral) (Alpha Cognition pipeline, September 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top